NCT00101166View on ClinicalTrials.gov

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Bystander-Based Autologous Tumor Cell Vaccine

The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

American Society of Clinical Oncology

OTHER

collaborator

Society of Surgical Oncology (SSO)

UNKNOWN

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00101166 - Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma | Biotech Hunter | Biotech Hunter